Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have sent them a mail ...
The objective of the JRC COVID-19 In Vitro Diagnostic Devices and Test Methods Database is to collect in a single place all publicly available information on performance of CE-marked in vitro diagnostic medical devices (IVDs) as well as laboratory-developed devices and related test methods for COVID-19. The database is manually curated and periodically updated.
Aim of the website
Browse the dataCOVID-19 in vitro diagnostic medical devices
The database contains publicly available in vitro diagnostic medical devices for COVID-19 and it is being updated periodically. Please note that additional performance (as retrieved from manufacturers web pages) is provided only for devices commercially available with CE-IVD mark.
Quick searches
All Immuno assay devices All Nucleic acid devices All CE Marking devices All Rapid antigen tests with CE Marking All Rapid antigen tests in HSC common list All Rapid antigen tests in HSC mutual recognition list
This section of the database is based on publicly available information from manufacturers.
The conformity of the devices with applicable EU law has NOT been in any way assessed by the European Commission or Member State national authorities for the purposes of inclusion in the database. There is no central approval system for in vitro diagnostic medical devices in the EU and the database does NOT represent a list of authorised or approved devices in the European Union.
For rapid antigen tests, as part of the EU Health Security Committee (HSC), the Member States have agreed on a common list of these tests considered appropriate for use in the context of COVID-19 diagnosis, as well as a selection of these whose results should be mutually recognised.
For more information, please read “Aim of the website”.
Great info dia ... thanks
Give hope ...
The problem with the current covid pandemic is that there are countless applications for approval. Sorrento has also submitted several. What would I say in Dr. Ji's place?
A- A lot of applications are being filed, I don't know when we will get to it, let's wait.
B- We have submitted our applications, we are waiting for an answer every day.
Otherwise, Sorrento is now too big to fail. Everything takes time ...
Ok, but never one from our messageboard ...
Of course, the shorties have contributed to the fact that the share price is not where it belongs. But that is only a question of patience. I have already lost a lot of money with shares, a miracle that I am still invested. After 20 years of experience, a stock like sorrento has to be damn good to make me even buy more ...
It would be nice if some of the posters here could exchange a working week with Dr. Ji. Then I would be curious to know whether he or she would still claim that Dr. Ji was a failure.
For me a surprise ...
SETTLEMENT DATE SHORT INTEREST AVG. DAILY VOLUME DAYS TO COVER
04/15/2021 59,553,984 8,095,839 7.356123
03/31/2021 55,975,027 7,807,811 7.169106
03/15/2021 56,069,379 12,038,408 4.657541
02/26/2021 56,944,678 11,890,850 4.788949
I think we go in the right direction, hehe ...
Just as I predicted , they close below 8 bucks, shit so called market ...
I know this shit so called market, we will closed over 8 bucks ...
Have also been home office for a year and retiring in 3 months just before my 66th birthday, not yet vaccinated ...
Very good News ...
blah, blah ...
How do you earn a living FitzyPissi ?
Great posting, thanks ...
Something is up ...
Ahh, here we go ...
So called market not open ??
Wow, not so bad ...
Great posting and very true ...
The trend is your friend ...
SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER
03/31/2021 55,975,027 7,807,811 7.169106
03/15/2021 56,069,379 12,038,408 4.657541
02/26/2021 56,944,678 11,890,850 4.788949
02/12/2021 64,146,101 20,352,665 3.15173
Chxal,The market does not decide whether Sorrento is successful or not, only investors like Blackrock or you and me do...
Oh, the market, wow, the market, this beautiful market.
I love this strong subject, so called THE MARKET.
This market, my friend is a deregulated pile of manure...
Jesspro, agree 100% ...
April 9, 2021 at 3:00 PM EDT
PALO ALTO, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido® to make efficacy labeling change with clinical data.
ZTlido® is the only lidocaine topical system that has been studied under the water stress conditions, and now has FDA label reflecting its use while showering, swimming and bathing. It gives polymer-based ZTlido® a competitive edge as other systems, especially water-based or hydrogel-based formulations, cannot be used when wet and must be removed prior to water exposure.
In the previous clinical trial (NCT04784728), a randomized, crossover, adhesion performance and pharmacokinetic study under conditions of water exposure in healthy subjects, Scilex had demonstrated that upon immersing the lidocaine topical system 1.8% (ZTlido®) in water, wet topical systems can be successfully reapplied, if necessary, and remain adhered for up to the labeled administration period of 12 hours. The trial showed that the topical system may be used while showering and that this does not increase lidocaine plasma levels. The topical systems were well-tolerated under all conditions and the dermal irritation profile was benign.
"We are very pleased with the trial outcome and labeling revision that attests to characteristics of ZTlido superior to other topical systems, to give patients a more reliable and uninterrupted drug delivery to alleviate pain associated with post-herpetic neuralgia," said Dmitri Lissin, MD, Chief Medical Officer of Scilex.
Criminal, I think you're out of your mind, go home you dumbass
Like always great work from your site, thanks ...
You are ranked 7160 ...
Is good, you are starting to be annoying. Can you not write a mail for the next 4 weeks ...
Bid size 142400 ... someone want shares
Whatever Henry Ji is saying behind the scenes is convincing enough that all of these acquisitions and partners are willing to take stock instead of cash...
Sure, we only need an EUA ...
Yes and now we can go 10% down,
Ok, why not ...
A great opportunity for Zack to release another sell rating, comon bring it on, I am waiting ...
Yes, this is the great so called market.
Create a important news and you closed red.
YES, its soooo normal ...
Like always, lot of work for shortie-pigs again and again ...
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the signing of a merger agreement pursuant to which Sorrento will acquire ACEA Therapeutics, Inc. (“ACEA”). The acquisition will include late clinical stage drug Abivertinib, clinical stage candidate AC0058, preclinical stage candidate AC0939, and ACEA’s extensive proprietary library of small molecules (over 1,000,000 compounds), which potentially have applications for numerous human disease indications, including non-small cell lung cancer (NSCLC), B cell lymphomas, systemic lupus, rheumatoid arthritis, multiple sclerosis and viral infections. These compounds are being actively studied in clinical trials and/or preclinical models to advance the most promising candidates rapidly to clinical stage development. Abivertinib, a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both a mutant form of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK), was originally identified from ACEA’s compound library. Abivertinib has the potential to improve outcomes in resistant prostate cancer, systemic lupus erythematosus, and various B cell lymphomas in addition to NSCLC, an indication for which a registrational/Phase 3 trial has been completed. It is currently being studied as a Phase 2 treatment for COVID-19-induced respiratory compromise in the US and Brazil. A second clinical candidate, AC0058, is a next generation BTK inhibitor, currently in a Phase 1b trial for Lupus patients in the US, which can potentially be expanded to other autoimmune diseases such as multiple sclerosis.
The acquisition will also include ACEA’s state of the art cGMP facility located in Quzhou, China, on a 23-acre campus with five buildings. This facility has successfully manufactured multiple batches of the active pharmaceutical ingredient (API) and final product in capsules for Abivertinib and AC0058 for clinical studies. The ACEA facility currently has capacity to manufacture up to 5,000 kg/year of APIs and 50,000,000 capsules of final drug product.
The ACEA next generation BTKi and other TKI small molecule drug candidates are highly synergistic with Sorrento’s broad biological product pipelines in therapeutic antibodies, antibody drug conjugates (ADCs), autologous chimeric antigen receptor-T (CAR-T) and allogeneic dimeric antigen receptor-T (DAR-T) cell therapies, oncolytic viruses and IL-2 immune modulators. The synergy will potentially enable Sorrento to develop many life-saving, combinational drugs for difficult-to-treat human illness in oncology, autoimmune and infectious diseases.
Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics, stated, “The ACEA acquisition will bring us a step closer to developing into a major biopharmaceutical company and we look forward to welcoming the ACEA team into the Sorrento family.”
As previously announced on October 16, 2020, Sorrento and ACEA entered into a letter of intent setting forth the terms and conditions by which Sorrento would acquire ACEA. In consideration for the acquisition, at the closing of the merger, ACEA’s equity holders will receive up to an aggregate of $38 million in shares of Sorrento common stock, subject to certain adjustments, based on a price per share calculated in accordance with the merger agreement. In addition to the foregoing consideration, and subject to the achievement of certain clinical and sales milestones (as described below), Sorrento will also pay the ACEA equity holders (i) up to $450,000,000 in additional payments, subject to the receipt of certain regulatory approvals and achievement of certain net sales targets with respect to the assets acquired in the merger and (ii) with respect to specified royalty-bearing products, five to ten percent of the annual net sales thereof, in each case in accordance with the terms of an earn-out agreement. The amount referenced in clause (i) of the preceding sentence includes the amounts that would have otherwise been due to ACEA under that certain License Agreement, dated July 13, 2020, which agreement will terminate in its entirety at the effective time of the merger.
The merger is expected to close in the second quarter of 2021, subject to customary closing conditions and regulatory approval. If the proposed merger is consummated, the issuance of the shares of Sorrento common stock would be made in accordance with an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) thereof and Regulation D and Regulation S thereunder. Such shares of Sorrento common stock would not be registered under the Securities Act and could not be offered or sold without registration unless an exemption from such registration is available. This press release does not constitute an offer to sell or the solicitation of an offer to buy, any shares of Sorrento common stock.
Perhaps:
After Dr. Ji has spoken, Dr. Fauci may asked, who is the company behind this Dr. Ji ???
Believe me, there will be many who would like to be there ...
My friend,
You always tend to see only the negative. But when I look at the many collaborations and investments that sorrento has made, I have no desire whatsoever to sell even a single share. On the contrary, I am buying more...